Eli Lilly Reports Positive Phase 3b Results for Ebglyss
Eli Lilly has reported positive phase 3b results for Ebglyss, with the topline disclosure signaling another late-stage win for the dermatology biologic ahead of full endpoint-level data.
Topic
Phase 3b
Topic
Phase 3b
Lebrikizumab Shows Rapid Gains in Hand and Foot Atopic Dermatitis
Lilly reports Phase 3b data showing EBGLYSS (lebrikizumab-lbkz) achieved significant, rapid improvements in skin clearance, itch,…
EBGLYSS Hits Endpoints in Phase 3b Hand-and-Foot Atopic Dermatitis Trial
Lilly's Phase 3b ADtouch trial shows 53% of hand-and-foot atopic dermatitis patients on EBGLYSS reached clear or almost clear ski…
Lebrikizumab Shows Rapid Gains in Hand and Foot Atopic Dermatitis
Lilly's Phase 3b data show EBGLYSS (lebrikizumab-lbkz) rapidly improved skin clearance, itch, pain, and patient satisfaction in m…